Recent News

• 09.11.2025 - Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
• 09.11.2025 - Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
• 09.11.2025 - Maze Therapeutics MZE782 Phase 1 Healthy Volunteer Results
• 09.11.2025 - Maze Therapeutics MZE782 Phase 1 Healthy Volunteer Results
• 09.11.2025 - Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
• 09.11.2025 - Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
• 09.11.2025 - Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
• 09.11.2025 - Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
• 09.09.2025 - Julian Harrison
• 09.09.2025 - Julian Harrison

Recent Filings

• 09.11.2025 - 8-K Current report
• 09.11.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 8-K Current report
• 09.02.2025 - 3 Initial statement of beneficial ownership of securities
• 09.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors